These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2611883)

  • 1. Reduced serotonin vascular sensitivity in ergotamine abusers.
    Panconesi A; Franchi G; Del Bianco PL; Anselmi B; Andreini R; Sicuteri F
    Cephalalgia; 1989 Dec; 9(4):259-64. PubMed ID: 2611883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery.
    Ostergaard JR; Mikkelsen E; Voldby B
    Cephalalgia; 1981 Dec; 1(4):223-8. PubMed ID: 7347625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients.
    Panconesi A; Anselmi B; Curradi C; Perfetto F; Piluso A; Franchi G
    Headache; 1994 Apr; 34(4):194-7. PubMed ID: 8014033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients.
    Panconesi A; Franchi G; Anselmi B; Curradi C; Tarquini B
    Cephalalgia; 1993 Dec; 13(6):383-8. PubMed ID: 8313451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients.
    Tfelt-Hansen P; Olesen J
    Acta Pharmacol Toxicol (Copenh); 1981 Jan; 48(1):69-72. PubMed ID: 6784444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man.
    Aellig WH
    Eur J Clin Pharmacol; 1983; 25(6):759-62. PubMed ID: 6662174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of ergotamine in migraine and cluster headache.
    Perrin VL
    Clin Pharmacokinet; 1985; 10(4):334-52. PubMed ID: 3899452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of serotonin and noradrenaline on superficial hand veins in patients with primary hypertension and in healthy volunteers.
    Wolzt M; Schmidt E; Wagner B; Schuller-Petrovic S; Kyrle PA; Eichler HG
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Nov; 346(5):490-5. PubMed ID: 1470220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ergotamine: its use in the treatment of migraine and its complications.
    Saxena VK; De Deyn PP
    Acta Neurol (Napoli); 1992 Apr; 14(2):140-6. PubMed ID: 1329442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Headache caused by analgesic and/or ergotamine abuse].
    Panconesi A; Del Bianco PL; Curradi C; Franchi G; Anselmi B; Andreini R
    Clin Ter; 1991 May; 137(3):169-83. PubMed ID: 1831085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of ergotamine abuse on psychological and cognitive functioning.
    Roon KI; Bakker D; van Poelgeest MI; van Buchem MA; Ferrari MD; Middelkoop HA
    Cephalalgia; 2000 Jun; 20(5):462-9. PubMed ID: 11037742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular adaptation in migraineurs with chronic daily headache.
    Hering R; Gardiner I; Catarci T; Whitmarsh T; Steiner T; de Belleroche J
    Cephalalgia; 1993 Aug; 13(4):261-6. PubMed ID: 8397071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration and uptake of 5-hydroxytryptamine in platelets from cluster headache and migraine patients.
    Waldenlind E; Ross SB; Sääf J; Ekbom K; Wetterberg L
    Cephalalgia; 1985 Mar; 5(1):45-54. PubMed ID: 3921257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of ergotamine-induced headache and ergotamine withdrawal on information processing.
    Evers S; Schmidt F; Bauer B; Voss H; Grotemeyer KH; Husstedt IW
    Psychopharmacology (Berl); 1999 Feb; 142(1):61-7. PubMed ID: 10102783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies.
    Cortijo J; Martí-Cabrera M; Bernabeu E; Domènech T; Bou J; Fernández AG; Beleta J; Palacios JM; Morcillo EJ
    Br J Pharmacol; 1997 Dec; 122(7):1455-63. PubMed ID: 9421295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up.
    Schnider P; Aull S; Baumgartner C; Marterer A; Wöber C; Zeiler K; Wessely P
    Cephalalgia; 1996 Nov; 16(7):481-5; discussion 461. PubMed ID: 8933992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ergotamine abuse. Do patients benefit from withdrawal?
    Tfelt-Hansen P; Krabbe A
    Cephalalgia; 1981 Mar; 1(1):29-32. PubMed ID: 15645831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ergotamine on isolated human vessels.
    Mikkelsen E; Pedersen OL; Ostergaard JR; Pedersen SE
    Arch Int Pharmacodyn Ther; 1981 Aug; 252(2):241-52. PubMed ID: 7305561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial infarction after chronic ergotamine abuse.
    Roithinger FX; Punzengruber C; Gremmel F; Hinterreiter M; Holzner F; Pachinger O
    Eur Heart J; 1993 Nov; 14(11):1579-81. PubMed ID: 8299645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ['Only ergotamine still helps'].
    Ferrari MD; Mulder LJ
    Ned Tijdschr Geneeskd; 1991 Jul; 135(27):1209-11. PubMed ID: 1861750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.